Response to treatment in prognostic subgroups
| . | FCCam . | FCR . | P . |
|---|---|---|---|
| All (n = 158) | |||
| CR | 15 | 27 | .12 |
| PR | 55 | 46 | |
| SD or PD | 8 | 7 | |
| Del 11q (n = 29) | |||
| CR | 7 | 4 | .43 |
| PR | 7 | 11 | |
| SD or PD | 2 | 1 | |
| Del 13q (n = 75) | |||
| CR | 9 | 15 | .33 |
| PR | 29 | 22 | |
| SD or PD | 3 | 3 | |
| IGVH mutated (n = 61) | |||
| CR | 4 | 9 | .46 |
| PR | 23 | 25 | |
| SD or PD | 3 | 2 | |
| IGVH unmutated (n = 92) | |||
| CR | 11 | 18 | .16 |
| PR | 32 | 21 | |
| SD or PD | 5 | 5 | |
| Binet stage B (n = 126) | |||
| CR | 13 | 23 | .21 |
| PR | 45 | 39 | |
| SD or PD | 3 | 3 | |
| Binet stage C (n = 32) | |||
| CR | 2 | 4 | .57 |
| PR | 10 | 7 | |
| SD or PD | 5 | 4 |
| . | FCCam . | FCR . | P . |
|---|---|---|---|
| All (n = 158) | |||
| CR | 15 | 27 | .12 |
| PR | 55 | 46 | |
| SD or PD | 8 | 7 | |
| Del 11q (n = 29) | |||
| CR | 7 | 4 | .43 |
| PR | 7 | 11 | |
| SD or PD | 2 | 1 | |
| Del 13q (n = 75) | |||
| CR | 9 | 15 | .33 |
| PR | 29 | 22 | |
| SD or PD | 3 | 3 | |
| IGVH mutated (n = 61) | |||
| CR | 4 | 9 | .46 |
| PR | 23 | 25 | |
| SD or PD | 3 | 2 | |
| IGVH unmutated (n = 92) | |||
| CR | 11 | 18 | .16 |
| PR | 32 | 21 | |
| SD or PD | 5 | 5 | |
| Binet stage B (n = 126) | |||
| CR | 13 | 23 | .21 |
| PR | 45 | 39 | |
| SD or PD | 3 | 3 | |
| Binet stage C (n = 32) | |||
| CR | 2 | 4 | .57 |
| PR | 10 | 7 | |
| SD or PD | 5 | 4 |